R
Robert A. Balk
Researcher at Rush University Medical Center
Publications - 177
Citations - 31415
Robert A. Balk is an academic researcher from Rush University Medical Center. The author has contributed to research in topics: Sepsis & Septic shock. The author has an hindex of 48, co-authored 165 publications receiving 29583 citations. Previous affiliations of Robert A. Balk include Rush Medical College & University of Oklahoma Health Sciences Center.
Papers
More filters
Journal ArticleDOI
Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis
Roger C. Bone,Robert A. Balk,F. B. Cerra,R. P. Dellinger,A. M. Fein,William A. Knaus,Roland M. H. Schein,W. J. Sibbald +7 more
TL;DR: An American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference was held in Northbrook in August 1991 with the goal of agreeing on a set of definitions that could be applied to patients with sepsis and its sequelae as mentioned in this paper.
Journal ArticleDOI
Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
Roger C. Bone,Robert A. Balk,F. B. Cerra,R. P. Dellinger,A. M. Fein,William A. Knaus,Roland M. H. Schein,W. J. Sibbald,WA Knous,J. H. Abrams,G. R. Bernard,JW Biondi,JE Calvin,R Demling,PJ Fahey,CJ Fisher,C Franklin,KJ Gorelick,MA Kelley,DG Maki,JC Marshall,WW Merrill,JP Pribble,EC Rackow,Timothy C. Rodell,JN Sheagren,Michael R. Silver,C. L. Sprung,Richard C. Straube,MJ Tobin,GM Trenholme,DP Wagner,CD Webb,JC Wherry,HP Wiedemann,CH Wortel,M. Kylänpää-Bäck +36 more
Journal ArticleDOI
A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.
Roger C. Bone,Charles J. Fisher,Terry P. Clemmer,Gus J. Slotman,Craig A. Metz,Robert A. Balk +5 more
TL;DR: It is concluded that the use of high-dose corticosteroids provides no benefit in the treatment of severe sepsis and septic shock.
Journal ArticleDOI
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
Charles J. Fisher,Jan M. Agosti,Steven M. Opal,Stephen F. Lowry,Robert A. Balk,Jerald C. Sadoff,Edward Abraham,Roland M. H. Schein,Ernest Benjamin +8 more
TL;DR: In patients with septic shock, treatment with the TNFR:Fc fusion protein does not reduce mortality, and higher doses appear to be associated with increased mortality.
Journal ArticleDOI
Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome
TL;DR: Study of lipopolysaccharide and cytokine levels in 97 patients with the sepsis syndrome found a positive correlation between high levels of plasma TNF- and mortality, and implicate T NF- as an important mediator in sepsi.